IONS Ionis Pharmaceuticals Inc.

50.05
+0.27  (1%)
Previous Close 49.78
Open 49.81
Price To book 20.26
Market Cap 6246014975
Shares 124,795,504
Volume 495,553
Short Ratio 11.43
Av. Daily Volume 917,611

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 trial initiation announced October 13, 2017.
IONIS-MAPTRx
Alzheimer's disease
Phase 2b initiation announced March 30, 2017. Data due 2018.
AKCEA-ANGPTL3-LRx
Rare hyperlipidemias
Phase 2b trial initiation announced January 5, 2017. Top-line data due 2019.
AKCEA-APOCIII-LRx
Hyperlipoproteinemia(a) and established cardiovascular disease
Phase 1/2 data to be presented 1H 2018, potentially at the Annual HD Therapeutics Conference February 26-March 1, 2018.
IONIS-HTT Rx
Huntington's Disease
Phase 2b completion of enrollment announced February 7, 2018. Data due 2H 2018.
AKCEA-APO(a)-LRx
Hyperlipoproteinemia(a) and established cardiovascular disease
Phase 1/2 interim data released November 2016.
IONIS-ANGPTL3-LRx
Cardiovascular disease
Phase 3 data released May 15, 2017 - primary endpoint met but with safety concerns. Data presented November 2, 2017. PDUFA date under priority review July 6, 2018.
Inotersen (IONIS-TTRRx)
NEURO-TTR - familial amyloid polyneuropathy (FAP).
Approved December 23, 2016.
SPINRAZA - Nusinersen
Spinal muscular atrophy (SMA)
Phase 2 data released November 2016.
IONIS-FXIRx
End-stage renal disease
Phase 2 data released 3Q 2015
IONIS-APO(a)Rx
High lipoprotein(a), or Lp(a)
Phase 2 data released January 4, 2016.
IONIS-GCGRRx
Type 2 diabetes
Phase 2 released Feb 2015. Achieved statistically significant results but data released was as of 36 weeks rather than 27 weeks for the primary endpoint
IONIS-PTP1BRx
Type 2 diabetes
Partner GSK announced May 2016 decision not to be proceed with Phase 3 outcome trial
Inotersen (IONIS-TTRRx)
CARDIO-TTR - Cardiomyopathy form of TTR amyloidosis.

Latest News

  1. Akcea Announces FDA Advisory Committee Meeting to Review Volanesorsen as a Treatment for Familial Chylomicronemia Syndrome
  2. The New England Journal of Medicine Publishes SPINRAZA® (nusinersen) Phase 3 Study Results in Individuals with Later-Onset Spinal Muscular Atrophy
  3. See what the IHS Markit Score report has to say about Ionis Pharmaceuticals Inc.
  4. Ionis Pharmaceuticals to Hold 2017 Financial Results Conference Call
  5. Akcea Completes Enrollment in Phase 2b Study of AKCEA-APO(a)-LRx
  6. How Biogen’s Spinraza Is Positioned for 2018
  7. Why 2017 Was a Year to Remember for Ionis Pharmaceuticals, Inc.
  8. Will 2018 Be Ionis Pharmaceuticals, Inc.'s Best Year Yet?
  9. Developments for Ionis Pharmaceuticals Post-3Q17
  10. How Akcea Therapeutics’ Volanesorsen Performed in 3Q17
  11. How Ionis’s Spinraza Performed in 3Q17
  12. A Look at Ionis’s 3Q17 Revenue Stream
  13. Exploring Ionis’s 3Q17 Quarterly Revenue Trend
  14. A Look at Ionis Pharmaceuticals’ January 2018 Valuation
  15. This Is Why Alnylam Pharmaceuticals Soared 249% in 2017
  16. Ionis' Inotersen NDA Accepted for Priority Review by the FDA
  17. Akcea Initiates Phase 2b Study of AKCEA-APOCIII-LRx in Patients with Hypertriglyceridemia and Established Cardiovascular Disease
  18. Implied Volatility Surging for Ionis Pharmaceuticals (IONS) Stock Options
  19. ETFs with exposure to Ionis Pharmaceuticals, Inc. : December 29, 2017